Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Background Nivolumab (Opdivo™) is a novel IgG4 subclass programmed death-1 (PD-1) inhibiting antibody that has demonstrated breakthrough-designation anti-tumor activity. To date, clinical trials of nivolumab and other checkpoint inhibitors have generally excluded patients with solid organ transplant...
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
BMJ Publishing Group
2016-11-01
|
| シリーズ: | Journal for ImmunoTherapy of Cancer |
| オンライン･アクセス: | https://jitc.bmj.com/content/4/1/64.full |